Citadel Advisors’s Solesence Inc SLSN Stock Holding History

Citadel Advisors’s Portfolio SLSN Stock Details SLSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-50,810	Closed	-$81K	–	14688
2025 Q4	$81K	Buy	+50,810	New	+$138K	﹤0.01%	11790

Other funds holding SLSN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Citadel Advisors's SLSN Position: Q1 2026 in Review

Citadel Advisors sold out of Solesence Inc (SLSN) in Q1 2026, closing a stake of 50,810 shares — an estimated $81K sold.

Citadel Advisors first reported a position in SLSN in Q4 2025 and held it in 1 quarter. The position peaked at $81K in Q4 2025. 49 funds tracked by Wall St. Rank hold SLSN as of Q1 2026.

Citadel Advisors reported no remaining Solesence Inc position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 50,810 Solesence Inc shares in Q1 2026, an estimated $81K.
Citadel Advisors first reported a position in Solesence Inc in Q4 2025 and held it in 1 quarter.
Citadel Advisors's Solesence Inc position peaked at $81K in Q4 2025.
49 funds tracked by Wall St. Rank held Solesence Inc as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.